Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: MisterED who wrote (2426)	11/12/1997 7:36:00 AM
From: BigKNY3	Respond to of 23519

Per: There are hardly any drugs that have therapeutic blood levels for only 10 minutes I believe the half life for Viagra is greater than 3 hours. BigKNY3

To: MisterED who wrote (2426)	11/12/1997 10:45:00 AM
From: Tunica Albuginea	Read Replies (1) \| Respond to of 23519

Per K. Reichborn " BigKN, "if he repeats the sexual stimulation" is not always the point, however, I have seen several times mentioned only ten minutes. I will try to find my source for this statement and post it if I can. ". The source is in The Brit J of Urology, the O N L Y Viagra article so far published in a peer reviewd medical journal : Per K. Reichborn " BigKN, "if he repeats the sexual stimulation" is not always the point, however, I have seen several times mentioned only ten minutes. I will try to find my source for this statement and post it if I can. ". The sours is in The Brit J of Urology, the O N L Y Viagra article so far published in a peer reviewd medical journal : First a recap of the Facts: exchange2000.com Sildenafil, a novel effective oral therapy for male erectile dysfunction. By Boolell M, Gepi-Attee S, Gingell JC, Allen MJ Department of Urology, Southmead Hospital, Westbury on Trym, Bristol, United Kingdom. Study F U N D E D BY P F I Z E R . ( This is their British laboratory ). OBJECTIVES: To determine the efficacy and safety of sildenafil, a novel orally active inhibitor of the type-V cyclic guanosine monophosphate-specific phosphodiesterase (the predominant isoenzyme in the human corpus cavernosum) on penile erectile activity in patients with male erectile dysfunction of no established organic cause. PATIENTS AND METHODS: Twelve patients (aged 36-63 years) with male erectile dysfunction of no established organic cause were entered into a double-blind, randomized, placebo-controlled, crossover study which was conducted in two phases. In the first phase (four-way crossover), treatment efficacy was evaluated by measurements of penile rigidity using penile plethysmography during visual sexual stimulation at different doses of sildenafil (10, 25 and 50 mg or placebo). In the second phase (two-way crossover), efficacy was assessed by a diary record of penile erectile activity after single daily doses of sildenafil (25 mg) or placebo for 7 days. RESULTS: The mean (95% confidence interval, CI) duration of rigidity of > 80% at the base of the penis was 1.3 min (0.4-3.1) in patients on placebo , 3.5 min (1.6-7.3; P = 0.009) on 10 mg, 8.0 min (3.7-16.7; P = 0.003) on 25 mg and 11.2 min (5.6-22.3; P < 0.001) on 50 mg of s i l d e n a f i l ( Viagra ). The mean (95% CI) duration of rigidity of > 80% at the tip of the penis was 1.2 min (0.4-2.7) on placebo and 7.4 min (2.4-8.5; P = 0.001) on 50 mg sildenafil. From the diary record of daily erectile activity, the mean (95% CI) total number of erections was significantly higher in patients receiving sildenafil was 6.1 (3.2-11.4), compared with 1.3 (0.5-2.7) in those on placebo; 10 of 12 patients reported improved erectile activity while receiving sildenafil, compared with two of 12 on placebo (P = 0.018). Six patients on active treatment and five on placebo reported mild and transient adverse events which included headache, dyspepsia and pelvic musculo-skeletal pain. exchange2000.com